Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Stryker is a global leader in the orthopaedic market and a major medical device manufacturer. Operations are segmented into Orthopaedic Implants (joint replacements, trauma, spine, micro implants, and orthobiologics) and MedSurg Equipment (powered surgical instruments, navigation systems, endoscopy, and patient handling equipment). The company also provides outpatient physical therapy services in the U.S.
Key Event: In the third quarter of 2004, Stryker acquired SpineCore, Inc., a developer of artificial lumbar and cervical discs, to enhance its spinal implant portfolio.
Key Financial Metrics
| Metric (in millions, except per share) | 2004 | 2003 |
|---|---|---|
| Net Sales | $4,262.3 | $3,625.3 |
| Gross Profit | $2,752.2 | $2,312.9 |
| Gross Margin | 64.6% | 63.8% |
| Operating Income | $720.4 | $671.3 |
| Net Earnings | $465.7 | $453.5 |
| Diluted EPS | $1.14 | $1.11 |
| Cash from Operations | $593.3 | $648.5 |
| Capital Expenditures | $187.8 | $144.5 |
| Total Assets | $4,083.8 | $3,159.1 |
| Long-Term Debt (incl. current) | $10.0 | $26.1 |
| Working Capital | $1,029.1 | $563.2 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% to $4,262.3 million, driven by a 17% increase in Orthopaedic Implants and a 20% increase in MedSurg Equipment. Growth was attributed to higher unit volumes, favorable foreign currency exchange rates (approx. 3% impact), and price increases.
- Acquisition Impact: The acquisition of SpineCore resulted in a one-time, non-cash charge of $120.8 million for purchased in-process research and development (IPR&D). This charge reduced reported net earnings by approximately 26% compared to an adjusted basis.
- Adjusted Earnings: Excluding the $120.8 million IPR&D charge, adjusted net earnings were $586.5 million, representing a 29% increase over 2003. Adjusted diluted EPS was $1.43.
- Debt Reduction: Long-term debt decreased significantly to $10.0 million as the company paid off substantially all borrowings under its credit facilities and accounts receivable securitization program.
- Expense Trends: R&D expenses rose 17% to $211.0 million (5.0% of sales) due to product launches and SpineCore development. SG&A expenses increased 17% to $1,652.2 million, partly due to higher insurance costs ($12.1 million increase) and sales commissions.
Guidance, Outlook, and Risks
- 2005 Outlook: Management expects diluted net earnings per share to approximate $1.74 (excluding stock option expense impact). Net sales are projected to increase approximately 15%, driven by Orthopaedic Implants and MedSurg growth, favorable currency, and Physical Therapy Services.
- Foreign Currency: If exchange rates hold at current levels, the company anticipates a favorable impact of approximately $75 million on full-year 2005 net sales.
- Regulatory & Legal Risks:
- DOJ Investigation: The company is cooperating with a Department of Justice investigation regarding billing and coding practices at its Physiotherapy Associates subsidiary (representing 6% of net sales).
- Product Liability: The company is partially self-insured for product liability claims and maintains reserves based on actuarial estimates.
- Reimbursement: Ongoing government and private-sector initiatives to limit healthcare costs could adversely affect product pricing and demand.
- Accounting Changes: The company plans to adopt FASB Statement No. 123(R) regarding share-based payments in Q3 2005, which will require recognizing stock option costs as an expense.
Investor Verification Checklist
- Adjusted vs. Reported Earnings: Verify the impact of the $120.8 million SpineCore IPR&D charge on reported profitability and review the non-GAAP reconciliation.
- SpineCore Milestones: Monitor the timeline for SpineCore's artificial disc commercialization (expected post-2008) and potential future milestone payments up to $240 million.
- DOJ Investigation Status: Track developments regarding the investigation into Physiotherapy Associates' billing practices and potential financial exposure.
- Foreign Currency Exposure: Assess the sensitivity of future earnings to fluctuations in the Euro and Japanese Yen, given 35% of sales are international.
- Stock Option Expense: Review the pro forma impact of the upcoming adoption of FASB 123(R) on future net earnings and EPS.